NEURANICS
8.12.2023 10:01:27 CET | Business Wire | Press release
Magnetic sensor specialist startup Neuranics has announced that it will launch a magnetic sensor development kit that will record the magnetic activity of the heart and wirelessly transfer this over Bluetooth for live 24/7 recording and analysis on a smartphone, tablet, or laptop.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231208190176/en/
(Photo: Neuranics)
Founded in 2021 as a spin-out from the Universities of Glasgow + Edinburgh, the company has recently secured pre seed funding of £1.9M led by Par Equity. Neuranics develops pioneering magnetic sensor technology for applications in the health, fitness, and metaverse sectors. Neuranics’ patented technology uses tunnelling magnetic resistance (TMR) to detect tiny magnetic signals in the muscles of the arms and body, which the company says can significantly improve health and fitness tracking and human / machine interfaces.
The company’s magnetocardiography (MCG) sensors have a single point of contact on the body, or through thin clothing, which will replace existing 3-lead electrocardiography (ECG) sensors for use in sports fitness devices and medical monitoring devices. The MCG signal gives greater resolution and clarity on the operation of the heart and can show blood movement within the main heart valves.
The development kit will come with the latest Neuranics magnetic sensor which can detect tiny magnetic signals from the heart muscle, prototype electronics, Bluetooth interface, software for analysis on a laptop and an app for Android mobile phones and tablets. The kit will allow developers to experiment with magnetic sensors and the software and app are highly customisable. The development kit will be available for purchase in early 2024 and will come with consultation and technical support.
CEO Noel McKenna said: “We are delighted to be launching the MCG development kit so quickly after our funding round. With our breakthrough technology sports, fitness and healthcare companies can develop new products based on the benefits of magnetic sensors. We look forward to welcoming attendees and fellow exhibitors for a live demonstration at our booth 60255 in Eureka Park at the Venetian Exhibition centre, CES 9th – 12th Jan 2024.”
To learn more about Neuranics, visit our website at http://neuranics.com/
To set up a meeting with the team during CES contact: info@neuranics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231208190176/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker sin tilstedeværelse i Argentina med Fidem Partners30.9.2026 15:20:00 CEST | Pressemeddelelse
Andersen Global udvider sine kompetencer inden for skat og transaktioner i Argentina gennem en samarbejdsaftale med Fidem Partners og styrker dermed sin tilstedeværelse og sit serviceudbud på markedet. Fidem Partners blev stiftet i 2011 og rådgiver virksomheder om skat og compliance, fusioner og opkøb samt outsourcing af forretningsprocesser. Firmaet betjener virksomheder inden for energi, teknologi, finansielle tjenester, landbrug og forbrugsvarer og har stor erfaring med at rådgive datterselskaber af multinationale virksomheder i Argentina. Det bredt sammensatte team trækker på erfaring fra førende rådgivningshuse og erhvervslivet for at hjælpe virksomheder gennem de vigtigste udviklingsfaser. "Det meste af vores arbejde udfører vi for datterselskaber af multinationale virksomheder, der opererer i Argentina, hvor de regulatoriske rammer kræver dømmekraft – ikke kun compliance," udtalte Darío H. Díaz, managing partner hos Fidem Partners. "Samarbejdet med Andersen Global giver vores kl
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 15:00:00 CEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 15:00:00 CEST | Press release
First deployment scheduled to enter service in 2026, combining industrial-scale infrastructure, proprietary inference software and long-term customer commitments. Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That m
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 15:00:00 CEST | Press release
Partnership brings PCI-validated P2PE and tokenization into 934’s connected hospitality payment infrastructure Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization fo
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness30.9.2026 14:59:00 CEST | Press release
Completed three-year PROTECT randomized controlled trial finds NaturalVue Multifocal 1 Day contact lens slowed myopia progression by 1.06 diopters and eye elongation by 0.58 mm at 36 months.1,2 Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational randomized controlled trial evaluating the company's NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens for slowing the progression of myopia, or nearsightedness, in children. Ashley Tuan, OD, MS, PhD, VTI's Chief Medical Officer, will present the full findings at the American Academy of Optometry's annual meeting in Anaheim. Myopia develops when a child's eye grows too long, causing distant objects to appear blurry, and it typically worsens through childhood. Faster progression is associated with a higher lifelong risk of more serious eye conditions, including retinal detachmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom